United Healthcare to Prefer Amgen’s Two Anticancer Biosimilars in October 2019

 United Healthcare to Prefer Amgen’s Two Anticancer Biosimilars in October 2019

UnitedHealthcare to Use Brand-Name for Pegfilgrastim from July’19

Shots:

  • In Oct’2019 United Healthcare plans utilizing Amgen’s Mvasi (biosimilar, bevacizumab) and Kanjinti (biosimilar, trastuzumab) as preferred products for commercial and community plans (but not Medicare Advantage), while with no longer preference to reference products Avastin and Herceptin  
  • Additionally, on Oct 1, 2019 Sandoz’s Zarxio (biosimilar filgrastim) will be listed as preferred product before use of follow-on filgrastim (Granix), brand-name filgrastim (Neupogen), or Pfizer’s biosimilar product (Nivestym) and also preferred Celltrion & Pfizer’s biosimilar (Inflectra), and Samsung Bioepis & Merck’s biosimilar (Renflexis) over brand name infliximab (Remicade)
  • Genentech’s Avastin (bevacizumab) is a mAb targeted to treat multiple indications of cancer and Herceptin (trastuzumab) is a mAb can be administered as an IV or as a SC infusion, binds to HER2 receptors present on the surface of HER2-positive tumor cells

Click here to read full press release/ article | Ref: United Healthcare | Image: BioWorld

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post